{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:24:42Z","timestamp":1759530282485,"version":"3.40.4"},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":831,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Cancer Care (Engl)"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1111\/ecc.12065","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T13:57:15Z","timestamp":1369317435000},"page":"605-611","source":"Crossref","is-referenced-by-count":12,"title":["A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome"],"prefix":"10.1155","volume":"22","author":[{"given":"N.","family":"Daver","sequence":"first","affiliation":[{"name":"Department of Leukaemia; The University of Texas MD Anderson Cancer Centre; Houston; TX; USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vega-Ruiz","sequence":"additional","affiliation":[{"name":"Department of Leukaemia; The University of Texas MD Anderson Cancer Centre; Houston; TX; USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukaemia; The University of Texas MD Anderson Cancer Centre; Houston; TX; USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Estrov","sequence":"additional","affiliation":[{"name":"Department of Leukaemia; The University of Texas MD Anderson Cancer Centre; Houston; TX; USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ferrajoli","sequence":"additional","affiliation":[{"name":"Department of Leukaemia; The University of Texas MD Anderson Cancer Centre; Houston; TX; USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kornblau","sequence":"additional","affiliation":[{"name":"Department of Leukaemia; The University of Texas MD Anderson Cancer Centre; Houston; TX; USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"Department of Leukaemia; The University of Texas MD Anderson Cancer Centre; Houston; TX; USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Garcia-Manero","sequence":"additional","affiliation":[{"name":"Department of Leukaemia; The University of Texas MD Anderson Cancer Centre; Houston; TX; USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukaemia; The University of Texas MD Anderson Cancer Centre; Houston; TX; USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,5,23]]},"reference":[{"key":"10.1111\/ecc.12065-BIB0002|ecc12065-cit-0001","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1517\/13543784.16.12.1967","article-title":"The role of azacitidine in the treatment of myelodysplastic syndromes","volume":"16","author":"Abdulhaq","year":"2007","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1111\/ecc.12065-BIB0003|ecc12065-cit-0002","first-page":"375","article-title":"Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas","volume":"70","author":"Ajani","year":"1986","journal-title":"Cancer Treatment Reports"},{"key":"10.1111\/ecc.12065-BIB0004|ecc12065-cit-0003","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/07357900701788122","article-title":"Treatment strategies in myelodysplastic syndromes","volume":"26","author":"Atallah","year":"2008","journal-title":"Cancer Investigation"},{"key":"10.1111\/ecc.12065-BIB0005|ecc12065-cit-0004","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/AAC.12.2.298","article-title":"Cytotoxicity and cell cycle specificity of homoharringtonine","volume":"12","author":"Baaske","year":"1977","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1111\/ecc.12065-BIB0006|ecc12065-cit-0005","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.seminhematol.2007.10.005","article-title":"Allogeneic stem cell transplantation for myelodysplastic syndrome","volume":"45","author":"Barrett","year":"2008","journal-title":"Seminars in Hematology"},{"key":"10.1111\/ecc.12065-BIB0007|ecc12065-cit-0006","first-page":"22","article-title":"[Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia]","volume":"29","author":"Bian","year":"1990","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1111\/ecc.12065-BIB0008|ecc12065-cit-0007","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V63.2.384.384","article-title":"Leukemic cell differentiation in vivo and in vitro: arrest of proliferation parallels the differentiation induced by the antileukemic drug Harringtonine","volume":"63","author":"Boyd","year":"1984","journal-title":"Blood"},{"key":"10.1111\/ecc.12065-BIB0001|ecc12065-cit-0009","first-page":"263","article-title":"Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment","volume":"2","author":"Cephalotaxus Research Coordinating Group","year":"1976","journal-title":"Chinese Medical Journal"},{"key":"10.1111\/ecc.12065-BIB0009|ecc12065-cit-0008","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1182\/blood-2007-02-076307","article-title":"Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders","volume":"110","author":"Chang","year":"2007","journal-title":"Blood"},{"key":"10.1111\/ecc.12065-BIB1001|ecc12065-cit-1001","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1111\/ecc.12065-BIB0010|ecc12065-cit-0010","first-page":"136","article-title":"Phase-I trial of homoharringtonine administered as a 5 day continuous infusion","volume":"24","author":"Coonley","year":"1983","journal-title":"Proceedings of the American Association for Cancer Research"},{"key":"10.1111\/ecc.12065-BIB0011|ecc12065-cit-0011","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"key":"10.1111\/ecc.12065-BIB0012|ecc12065-cit-0012","first-page":"1189","article-title":"Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia","volume":"6","author":"Feldman","year":"1992a","journal-title":"Leukemia"},{"key":"10.1111\/ecc.12065-BIB0013|ecc12065-cit-0013","first-page":"1185","article-title":"Homoharringtonine is safe and effective for patients with acute myelogenous leukemia","volume":"6","author":"Feldman","year":"1992b","journal-title":"Leukemia"},{"key":"10.1111\/ecc.12065-BIB0014|ecc12065-cit-0014","first-page":"40","article-title":"Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia","volume":"10","author":"Feldman","year":"1996","journal-title":"Leukemia"},{"key":"10.1111\/ecc.12065-BIB0015|ecc12065-cit-0015","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"The Lancet Oncology"},{"key":"10.1111\/ecc.12065-BIB0016|ecc12065-cit-0016","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1432-1033.1977.tb11256.x","article-title":"Inhibition of translation in eukaryotic systems by harringtonine","volume":"72","author":"Fresno","year":"1977","journal-title":"European Journal of Biochemistry"},{"key":"10.1111\/ecc.12065-BIB0017|ecc12065-cit-0017","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1111\/ecc.12065-BIB0018|ecc12065-cit-0018","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/jnci\/80.14.1095","article-title":"Cephalotaxine esters: antileukemic advance or therapeutic failure?","volume":"80","author":"Grem","year":"1988a","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1111\/ecc.12065-BIB0019|ecc12065-cit-0019","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/jnci\/80.14.1095","article-title":"Cephalotaxine esters: antileukemic advance or therapeutic failure?","volume":"80","author":"Grem","year":"1988b","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1111\/ecc.12065-BIB0020|ecc12065-cit-0020","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0026-895X(25)10662-7","article-title":"Harringtonine, an inhibitor of initiation of protein biosynthesis","volume":"11","author":"Huang","year":"1975","journal-title":"Molecular Pharmacology"},{"key":"10.1111\/ecc.12065-BIB0021|ecc12065-cit-0021","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1002\/cncr.25247","article-title":"Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy","volume":"116","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"key":"10.1111\/ecc.12065-BIB0022|ecc12065-cit-0022","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/10428190701216360","article-title":"Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathway","volume":"48","author":"Jie","year":"2007","journal-title":"Leukemia and Lymphoma"},{"key":"10.1111\/ecc.12065-BIB0023|ecc12065-cit-0023","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"10.1111\/ecc.12065-BIB0024|ecc12065-cit-0024","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/1097-0142(19890301)63:5<813::AID-CNCR2820630502>3.0.CO;2-V","article-title":"Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia","volume":"63","author":"Kantarjian","year":"1989","journal-title":"Cancer"},{"key":"10.1111\/ecc.12065-BIB0025|ecc12065-cit-0025","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U","article-title":"Homoharringtonine: history, current research, and future direction","volume":"92","author":"Kantarjian","year":"2001","journal-title":"Cancer"},{"key":"10.1111\/ecc.12065-BIB0026|ecc12065-cit-0026","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2002.04.044","article-title":"Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study","volume":"20","author":"Kornblith","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/ecc.12065-BIB0027|ecc12065-cit-0027","first-page":"69","article-title":"Influence of harringtonine on human leukemia cell differentiation","volume":"37","author":"Kuliczkowski","year":"1989","journal-title":"Archivum Immunologiae et Therapiae Experimentalis"},{"key":"10.1111\/ecc.12065-BIB0028|ecc12065-cit-0028","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.bjc.6603265","article-title":"A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia","volume":"95","author":"Levy","year":"2006","journal-title":"British Journal of Cancer"},{"key":"10.1111\/ecc.12065-BIB0029|ecc12065-cit-0029","first-page":"303","article-title":"Combined harringtonine or homoharringtonine chemotherapy for acute nonlymphocytic leukemia in 25 children","volume":"96","author":"Li","year":"1983","journal-title":"Chinese Medical Journal"},{"key":"10.1111\/ecc.12065-BIB0030|ecc12065-cit-0030","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/sim.3805","article-title":"On Simon's two-stage design for single-arm phase IIA cancer clinical trials under Beta-binomial distribution","volume":"29","author":"Liu","year":"2010","journal-title":"Statistics in Medicine"},{"key":"10.1111\/ecc.12065-BIB0031|ecc12065-cit-0031","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood.V86.9.3322.bloodjournal8693322","article-title":"Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase","volume":"86","author":"O'Brien","year":"1995","journal-title":"Blood"},{"key":"10.1111\/ecc.12065-BIB0032|ecc12065-cit-0032","first-page":"A555","article-title":"Homoharringtonine induces apoptosis in chronic myelogenous leukemia-cells","volume":"82","author":"Obrien","year":"1993","journal-title":"Blood"},{"key":"10.1111\/ecc.12065-BIB0033|ecc12065-cit-0033","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1080\/10428190701471981","article-title":"Decitabine and its role in the treatment of hematopoietic malignancies","volume":"48","author":"Plimack","year":"2007","journal-title":"Leukemia and Lymphoma"},{"key":"10.1111\/ecc.12065-BIB0034|ecc12065-cit-0034","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1517\/14656566.9.6.1029","article-title":"Homoharringtonine for the treatment of chronic myelogenous leukemia","volume":"9","author":"Quintas-Cardama","year":"2008a","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1111\/ecc.12065-BIB0035|ecc12065-cit-0035","first-page":"356","article-title":"Omacetaxine mepesuccinate - a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies","volume":"11","author":"Quintas-Cardama","year":"2008b","journal-title":"IDrugs"},{"key":"10.1111\/ecc.12065-BIB0036|ecc12065-cit-0036","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/ecc.12065-BIB0037|ecc12065-cit-0037","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF00258117","article-title":"Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells","volume":"14","author":"Takemura","year":"1985","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1111\/ecc.12065-BIB0038|ecc12065-cit-0038","first-page":"1245","article-title":"Phase I trial of homoharringtonine in children with refractory leukemia","volume":"71","author":"Tan","year":"1987","journal-title":"Cancer Treatment Reports"},{"key":"10.1111\/ecc.12065-BIB0039|ecc12065-cit-0039","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0014-5793(89)81546-7","article-title":"Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation","volume":"257","author":"Tujebajeva","year":"1989","journal-title":"FEBS Letters"},{"key":"10.1111\/ecc.12065-BIB0040|ecc12065-cit-0040","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.leu.2400608","article-title":"Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on \u2018in vitro\u2019 growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors","volume":"11","author":"Visani","year":"1997","journal-title":"Leukemia"},{"key":"10.1111\/ecc.12065-BIB0041|ecc12065-cit-0041","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1200\/JCO.1985.3.5.617","article-title":"Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia","volume":"3","author":"Warrell","year":"1985","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/ecc.12065-BIB0042|ecc12065-cit-0042","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ajh.20100","article-title":"Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP)","volume":"76","author":"Yinjun","year":"2004","journal-title":"American Journal of Hematology"},{"key":"10.1111\/ecc.12065-BIB0043|ecc12065-cit-0043","first-page":"2031","article-title":"Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro","volume":"50","author":"Zhou","year":"1990","journal-title":"Cancer Research"}],"container-title":["European Journal of Cancer Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fecc.12065","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ecc.12065\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T11:06:11Z","timestamp":1746011171000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ecc.12065"}},"subtitle":["A phase II open-label study of the intravenous"],"short-title":[],"issued":{"date-parts":[[2013,5,23]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"URL":"https:\/\/doi.org\/10.1111\/ecc.12065","relation":{},"ISSN":["0961-5423"],"issn-type":[{"type":"print","value":"0961-5423"}],"subject":[],"published":{"date-parts":[[2013,5,23]]}}}